Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Journal of Clinical Medicine
|
February 25, 2023
Correlation of <i>UGT1A1</i> Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
Kazuaki Harada, Takahiro Yamamura, Osamu Muto, et al.
JCO Precision Oncology
|
January 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial
Mitsuho Imai, Yoshiaki Nakamura, Sangwon Shin, et al.
The Oncologist
|
May 17, 2022
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, et al.
Esophagus : Official Journal of the Japan Esophageal Society
|
April 20, 2026
Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response
Yuho Ebata, Eiji Oki, Qingjiang Hu, et al.
BMC Cancer
|
December 10, 2017
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
Yasuyuki Kawamoto, Yoshito Komatsu, Satoshi Yuki, et al.
The Journal of Vascular Access
|
September 19, 2025
Evaluation of a novel standardized education program for centrally inserted central catheters insertion in a region of Japan
Fumito Saijo, Yutaro Arata, Naoya Akazawa, et al.
International Journal of Cancer
|
August 14, 2024
A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801
Hiroshi Nakatsumi, Yoshito Komatsu, Kazuaki Harada, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 19, 2026
Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)
Kazuaki Harada, Shinya Kajiura, Kentaro Sawada, et al.
Frontiers in Cellular and Infection Microbiology
|
October 3, 2022
Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
Shunsuke A Sakai, Masato Aoshima, Kentaro Sawada, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
May 4, 2026
A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)
Yasuyuki Kawamoto, Kentaro Sawada, Kazuaki Harada, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Journal of Clinical Medicine
|
February 25, 2023
Correlation of <i>UGT1A1</i> Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
Kazuaki Harada, Takahiro Yamamura, Osamu Muto, et al.
JCO Precision Oncology
|
January 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial
Mitsuho Imai, Yoshiaki Nakamura, Sangwon Shin, et al.
The Oncologist
|
May 17, 2022
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, et al.
Esophagus : Official Journal of the Japan Esophageal Society
|
April 20, 2026
Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response
Yuho Ebata, Eiji Oki, Qingjiang Hu, et al.
BMC Cancer
|
December 10, 2017
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
Yasuyuki Kawamoto, Yoshito Komatsu, Satoshi Yuki, et al.
The Journal of Vascular Access
|
September 19, 2025
Evaluation of a novel standardized education program for centrally inserted central catheters insertion in a region of Japan
Fumito Saijo, Yutaro Arata, Naoya Akazawa, et al.
International Journal of Cancer
|
August 14, 2024
A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801
Hiroshi Nakatsumi, Yoshito Komatsu, Kazuaki Harada, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 19, 2026
Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)
Kazuaki Harada, Shinya Kajiura, Kentaro Sawada, et al.
Frontiers in Cellular and Infection Microbiology
|
October 3, 2022
Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
Shunsuke A Sakai, Masato Aoshima, Kentaro Sawada, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
May 4, 2026
A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)
Yasuyuki Kawamoto, Kentaro Sawada, Kazuaki Harada, et al.
Page
of 6